Clinical Trials Directory

A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Sorafenib (Nexavar, BAY43-9006)
  • drug : Placebo

Phase: Phase 3


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell) - Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are eligible provided that the histology has no medullary differentiation nor anaplastic features - Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors] should be used as a basis for the assessment of disease progression) - RAI (radioactive iodine) refractory

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting

Footer Links: